Artios

Artios is a leading independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Artios began clinical trials in February 2021 of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumours. Established in May 2016, th...